Author Correction: Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy

Thomas Walle, Sunanjay Bajaj, Joscha A. Kraske, Thomas Rösner, Christiane S. Cussigh, Katharina A. Kälber, Lisa Müller, S Strobel, Jana Burghaus, Stefan M. Kallenberger, Christoph Stein-Thöringer, Maximilian Jenzer, Antonia Schubert, Steffen Kahle, Anja Williams, Birgit Hoyler, Lin Zielske, Renate Skatula, Stefanie Sawall, Mathias F. Leber, Russell Kunes, Johannes Krisam, Carlo Fremd, Andreas Schneeweiß, Jürgen Krauß, Leonidas Apostolidis, Anne Berger, Georg Martin Haag, Stefanie Zschäbitz, Niels Halama, Christoph Springfeld, Romy Kirsten, Jessica C. Hassel, Dirk Jäger, Omar Abdelrahim, Elena Busch, Patrick Derigs, Katharina Dischinger, Fouad Mitri, Kerstin Schmidt, Irfan A. Bhatti, Barbara Grün, Nicolas Hohmann, Lena Woydack, Xin-Wen Zhang, Dyke Ferber, Andreas Mock, Tillmann Pompecki, Timo Schank, Guy UngerechtsNature Cancer 2022 · DOI · OpenAlex

Introduction

This article provides a formal Author Correction for the study originally published in Nature Cancer titled "Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy." The primary objective of this update is to rectify the reporting of patient safety outcomes. Specifically, the correction addresses an omission in the original abstract regarding the frequency and nature of serious adverse events (SAEs) observed during the study period.

The Research Context

The original investigation sought to determine if COVID-19 vaccinations posed a unique risk to oncology patients receiving immunotherapy. Given that immunotherapy modulates the immune system, there was a theoretical concern that vaccines might trigger "cytokine storms" or Cytokine Release Syndrome (CRS)—a systemic inflammatory response that can be life-threatening.

The study's initial findings indicated that while many patients exhibited serum cytokine profiles similar to those seen in CRS, they did not manifest the clinical symptoms of the syndrome. The authors termed this phenomenon "clinically inapparent." However, to provide a complete clinical picture, it was necessary to detail all serious health events that occurred in the cohort following vaccination, regardless of their direct causal link to the vaccine.

Updated Clinical Outcomes

The correction introduces specific quantitative data regarding the safety profile of the patient cohort (approximately 64 patients) within the four weeks following vaccination. The revised abstract now includes the following critical findings:

  • Serious Adverse Events (SAEs): Eight patients, representing 12.5% of the cohort (95% CI 5.6–23%), experienced SAEs.
  • Hospitalization Patterns: Six of these patients required hospitalization. The authors clarify that these hospitalizations were due to events "common under cancer therapy," such as immune-related adverse events (irAEs) that are expected complications of checkpoint inhibitor therapies.
  • Mortality Reporting: Two patients died within the four-week observation window. The correction specifies that these deaths were due to "conditions present before vaccination," rather than being a direct consequence of the vaccine itself.

Analysis of Patient Safety

The inclusion of these details provides essential nuance to the study's conclusions. By distinguishing between vaccine-induced cytokine responses and the broader clinical outcomes of a high-risk population, the authors offer a more transparent view of the risks involved.

The reported 12.5% SAE rate, while significant, must be interpreted within the context of advanced cancer treatment. The fact that the majority of these events were typical of cancer therapy or pre-existing conditions reinforces the study's original premise: that the specific "CRS-like" cytokine response triggered by the vaccine does not translate into acute clinical instability for most patients. Furthermore, the provision of the 95% Confidence Interval (5.6–23%) allows clinicians to better understand the statistical range of risk when advising patients on vaccination.

Conclusion

This Author Correction serves as a vital update for the oncology community. While it confirms that COVID-19 vaccines are generally well-tolerated in terms of not inducing clinical CRS, it highlights the necessity of rigorous, transparent reporting of all adverse events in vulnerable populations. The update ensures that the term "clinically inapparent" is not misconstrued as an absence of clinical risk, but rather a specific observation regarding the nature of the vaccine-induced immune response in the context of ongoing cancer immunotherapy.

This summary is based on the Author Correction published in Nature Cancer.

Summary updated

Abstract

In the version of this article initially published, salient aspects of patient outcomes were not clearly articulated in the abstract, which has now been revised to include the text "Within 4 weeks after vaccination, serious adverse events occurred in eight patients (12.5% 95% CI 5.6-23%): six patients were hospitalized due to events common under cancer therapy including immune related adverse events and two patients died due to conditions present before vaccination". The changes have been made in the HTML and PDF versions of the article.
BibTeX
@inproceedings{walle2022author,
  author = {Thomas Walle and Sunanjay Bajaj and Joscha A. Kraske and Thomas Rösner and Christiane S. Cussigh and Katharina A. Kälber and Lisa Müller and S Strobel and Jana Burghaus and Stefan M. Kallenberger and Christoph Stein-Thöringer and Maximilian Jenzer and Antonia Schubert and Steffen Kahle and Anja Williams and Birgit Hoyler and Lin Zielske and Renate Skatula and Stefanie Sawall and Mathias F. Leber and Russell Kunes and Johannes Krisam and Carlo Fremd and Andreas Schneeweiß and Jürgen Krauß and Leonidas Apostolidis and Anne Berger and Georg Martin Haag and Stefanie Zschäbitz and Niels Halama and Christoph Springfeld and Romy Kirsten and Jessica C. Hassel and Dirk Jäger and Omar Abdelrahim and Elena Busch and Patrick Derigs and Katharina Dischinger and Fouad Mitri and Kerstin Schmidt and Irfan A. Bhatti and Barbara Grün and Nicolas Hohmann and Lena Woydack and Xin-Wen Zhang and Dyke Ferber and Andreas Mock and Tillmann Pompecki and Timo Schank and Carlo Fremd and Georg Martin Haag and Niels Halama and Romy Kirsten and Jessica C. Hassel and Dirk Jäger and Guy Ungerechts and Guy Ungerechts},
  title = {{Author Correction: Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy}},
  booktitle = {Nature Cancer},
  year = {2022},
  doi = {10.1038/s43018-022-00420-y},
}
Figure